Chicago Partners Investment Group LLC Has $239,000 Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Chicago Partners Investment Group LLC raised its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 21.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 134,851 shares of the company’s stock after buying an additional 23,740 shares during the quarter. Chicago Partners Investment Group LLC owned 0.07% of Taysha Gene Therapies worth $239,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Howard Capital Management Inc. acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth approximately $25,000. Victory Capital Management Inc. acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth approximately $28,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth approximately $38,000. Finally, Williams & Novak LLC acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth approximately $80,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Down 26.3 %

Shares of NASDAQ TSHA opened at $2.97 on Wednesday. The firm’s 50-day simple moving average is $3.00 and its 200 day simple moving average is $2.38. The company has a market cap of $555.45 million, a price-to-earnings ratio of -6.06 and a beta of 0.49. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies, Inc. has a 12-month low of $0.50 and a 12-month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $3.41 million for the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter in the prior year, the company earned ($0.28) EPS. On average, research analysts expect that Taysha Gene Therapies, Inc. will post -0.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Canaccord Genuity Group reissued a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, May 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $8.00 target price (up previously from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Finally, Piper Sandler started coverage on shares of Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an “overweight” rating and a $9.00 target price on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.00.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.